Cover image not available

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for advanced and/or metastatic renal cell carcinoma : Understanding NICE guidance :

National Institute for Health and Clinical Excellence

Publication Data

Title Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for advanced and/or metastatic renal cell carcinoma : Understanding NICE guidance :
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and Clinical Excellence
Publication date 2009
Publication location London
Language English

Descriptive Notes

Issue date: August 2009.
Publisher's number: N1984.

Topics

Renal cell carcinoma :: Chemotherapy :: England
Renal cell carcinoma :: Chemotherapy :: Wales

Catalogue Data

OBNB ID GBB586048
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99461061

ISBD

P1053 1 online resource (4 unnumbered pages).

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for advanced and/or metastatic renal cell carcinoma : Understanding NICE guidance : by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence in 2009. Publication and catalogue information, links to buy online and reader comments.